logo
A new harm reduction group is creating a safe space to do drugs in St. John's

A new harm reduction group is creating a safe space to do drugs in St. John's

Yahoo15 hours ago

In response to an increasing number of overdose deaths in Newfoundland and Labrador, a new group of harm reduction advocates are opening what they say is St. John's first overdose prevention site.
Overdose Awareness and Response St. John's (OARS) provides safe use supplies and naloxone, and its founder says both volunteers and nurses trained in overdose intervention are on hand.
"Whether that's folks that are street-entrenched or just folks downtown partying, we provide a space where people can do drugs in safety," said Luca Schaefer.
Schaefer describes the operation as similar to a supervised consumption site, which are controversial in Canada. The Health Canada website describes such sites as "a safe, clean space for people to bring their own drugs to use, in the presence of trained staff. This prevents accidental overdoses and reduces the spread of infectious diseases, such as HIV."
Individuals or organizations who want to open a supervised consumption site can ask the federal government for an exemption from the Controlled Drugs and Substances Act, but OARS has not yet made an application.
In contrast, overdose prevention sites — which Health Canada also calls urgent public-health needs sites — "are established on a temporary basis to respond to urgent needs in a specific region or community."
Ottawa can authorize the provincial health minister to set up one of these sites, but in an emailed statement to CBC News, spokesperson Khadija Rehma said OARS has not yet contacted the Health Department.
"We appreciate the valuable work of community organizations and volunteers to ensure safe substance use supports and services," the statement said.
Newfoundland and Labrador Health Services spokesperson Mikaela Etchegary said the provincial health authority supports harm reduction efforts, but hasn't established an official partnership with OARS.
Rigel Penman, a volunteer with OARS, told CBC News the group hasn't yet applied for legal exemption because it's still in talks with various levels of government.
Penman said OARS is trying to set up as "quickly as possible," especially with summer around the corner, and says the group decided not to wait for what could be a lengthy application process.
WATCH | Harm reduction advocates create pop-up overdose prevention site in St. John's:
The site won't supply or provide substances, Schaefer said.
"If using in the space is what they need at the moment, then we're able to provide that support. And if not, they're free to take what they need," she said.
For now, the site will be a pop-up tent in downtown St. John's — a setup that's "able to move and be wherever is needed or necessary," said Schaefer.
OARS has run the site twice so far, on the evenings of May 23 and May 30. Schaefer says public response has been mixed, with some people approaching to get supplies, and others expressing curiosity or negativity.
"This group is addressing and providing support to a marginalized and at-risk population," she said. "We should be looking to our most vulnerable people and asking ourselves what we're able to do to step up."
Overdose prevention and supervised consumption sites were a talking point during the latest federal election, with Conservative Leader Pierre Poilievre calling them "drug dens" and a "bizarre social experiment" and vowing to restrict them.
According to Health Canada, supervised consumption sites operate in Alberta, Saskatchewan, Ontario, Quebec and British Columbia.
The first site opened in Vancouver in 2003, and the model spread throughout the country in the ensuing decades. In 2016, as overdose deaths skyrocketed, several unsanctioned overdose prevention tents sprung up in the city's Downtown Eastside — ground zero for Canada's opioid crisis.
Activists at the time told CBC the pop-up sites were an effort to save lives without waiting for sluggish bureaucratic approval.
Last year, however, Ontario implemented a new law banning drug consumption sites near schools and child-care centres. That law forced the closure of nine sites in Ontario, despite a court injunction allowing them to remain open while a judge to examines the law's constitutionality.
Schaefer says she's ready to respond to concerns from the community.
In April, the RCMP warned of rising drug toxicity deaths in the province, and said cocaine is now the leading drug responsible for overdose deaths.Seventy-four people died from consuming drugs in Newfoundland and Labrador last year.
Last month, police seized a record amount of fentanyl from a St. John's trailer — enough to kill nearly half the province.
Schaefer says OARS is responding to those statistics.
"There's a lot of reasons why people use drugs," she said. "They shouldn't have to worry about whether or not the drugs that they're gonna take are going to kill them."
OARS outreach advocate Loo Vatcher says Newfoundland and Labrador is in desperate need of better overdose prevention.
"This world is hard enough for all of us, and whether we like it or not, people are going to use substances," they said. "It's really important that we meet people where they're at."
OARS will run a site once a week for now, but Vatcher says its long-term goal is to set up an indoor location to host safe use and harm reduction services.
For that to happen, OARS will be fundraising more money, applying for government grants and continuing its advocacy.
Vatcher said volunteers want to "put a bit of pressure on the government to do what's right, to help us create the safe space for people who deserve it."
Download our free CBC News app to sign up for push alerts for CBC Newfoundland and Labrador. Sign up for our daily headlines newsletter here. Click here to visit our landing page.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally
Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally

Yahoo

time4 hours ago

  • Yahoo

Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally

OTTAWA, ON, June 6, 2025 /CNW/ - Summary Product: Various nitrous oxide products Issue: Health products – Product safety; Unauthorized product What to do: Do not inhale nitrous oxide products for recreational purposes. If you use prescription nitrous oxide recreationally and experience side effects, seek medical attention immediately. Affected productsVarious nitrous oxide products. Examples of seized products include: Bamboozle Need Whip Primewhip Primewhip XL Space Gas IssueHealth Canada is warning consumers about the serious health risks, including death, of inhaling nitrous oxide products, also known as laughing gas and by various street names, such as "whippets," "hippy crack," "NOS" and "nang," for recreational purposes. In Canada, nitrous oxide sold for inhalation is a drug and can only be administered by an authorized health care professional for legitimate and safe uses, such as in medical and dental procedures for sedation and pain relief. It is also in cream dispensers and other food tools where it is not meant to be inhaled. When inhaled—or "huffed" —nitrous oxide can cause euphoria and relaxation. It can also cause serious adverse effects such as: loss of consciousness and in some cases, death birth defects anemia, vitamin B12 deficiency impaired bowel and bladder function confusion, agitation, delusions, hallucinations, paranoia and depression increased heart rate, palpitations, low blood pressure, heart attack and stroke lack of oxygen in the body (asphyxia), blood clots in the extremities and in the lungs, and air leaks into the space between the lung and chest wall (pneumothorax) tingling, numbness and weakness of the limbs and extremities (fingers and toes), uncoordinated walking and falls nerve damage, spinal cord degeneration, prolonged pain and, in severe cases, permanent paralysis Repeated use increases the likelihood of severe outcomes and may result in lasting neurological damage, even after stopping use. Regular use can also lead to addiction and withdrawal symptoms. Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited. However, Health Canada is aware that these products are being sold online and in retail stores. These products may be deceptively labelled: as "whip cream chargers," in flavours, which are not permitted, in stores you would not expect to find whipped cream chargers; and in large containers you would not expect for dispensing whipped cream. Health Canada has not reviewed these products, which are regulated as drugs, for safety, efficacy or quality. Also, they could be contaminated in ways that create additional health risks when inhaled. Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes. Health Canada has seized several unauthorized nitrous oxide products and has worked with Canada Border Services Agency (CBSA) to stop unauthorized shipments from entering the country. The Department will continue to take action to stop the sale of unauthorized products and to work with CBSA to help prevent further importations. What you should do Do not inhale nitrous oxide products for recreational purposes. Seek immediate medical attention from a health care professional (physician, nurse, pharmacist, Canadian Poison Centre) if you have used nitrous oxide recreationally or for medical purposes and have experienced any side effects. For Poison Centre access you can contact 1-844 POISON-X, in Quebec 1-800-463-5060, or contact your local poison centre directly. Health Canada has also published information about stopping substance use. Report any health product-related side effects or complaints to Health Canada. Également disponible en français SOURCE Health Canada (HC) View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Public Advisory - One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only)
Public Advisory - One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only)

Yahoo

time4 hours ago

  • Yahoo

Public Advisory - One lot of Seasonique birth control recalled due to possible extra yellow pills (ethinyl estradiol only)

OTTAWA, ON, June 6, 2025 /CNW/ - Summary Product: Seasonique (DIN 02346176) Issue: Health products - Product quality What to do: Do not skip doses or stop taking Seasonique. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return the product to your pharmacy for a replacement or alternative product. If you cannot get to a pharmacy right away, take the next blue-green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. Affected products: Product DIN Lot Expiry Seasonique (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, and 0.01 mg ethinyl estradiol) 02346176 100069151 31-Jan-2027 Issue Teva Canada Ltd. is recalling one lot of Seasonique prescription birth control due to the possibility of having an extra row of yellow pills in tray 1 and/or 2 of the blister cards, where there should be none. This may increase the risk of pregnancy. When packaged correctly, as shown in the picture, Seasonique pills come in extended-cycle tablet dispensers, each containing a 13-week (91-day) supply of pills divided in three blister cards: Tray 1 and Tray 2 each contain a blister card with 28 blue-green tablets (levonorgestrel and ethinyl estradiol) Tray 3 contains a blister card with 35 tablets: 28 blue-green tablets (levonorgestrel and ethinyl estradiol) and 7 yellow tablets (ethinyl estradiol) Users can expect to have four periods a year, with bleeding occurring while taking the yellow pills. Seasonique should be taken daily unless otherwise directed by your prescriber. Taking the pills in the proper order, according to the product instructions, is important for preventing pregnancy. Taking the wrong pill or a pill out of order could lead to an unplanned pregnancy or other side effects, including spotting and irregular bleeding. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions. The Department will inform the public if any new health risks are identified. What you should do: Do not stop taking Seasonique. Do not skip taking any blue–green pills. Check your package. If your package contains an extra row of yellow pills in Tray 1 and/or 2 of the blister cards, do not take them. Instead, return it to your pharmacy for a replacement or an alternative product. If you cannot get to a pharmacy right away, take the next blue–green pill in the proper order as noted in the instructions until you are able to contact your pharmacist and obtain a replacement or alternative product. If you are unsure whether your package contains the correct pills, talk to your pharmacist. If you took a yellow pill instead of a blue-green pill from Tray 1 and/or 2, or if you are unsure, you should also use another method of non-hormonal back-up contraception (such as condoms) and consult with your health care professional. Talk to a health care professional if you have any other questions or concerns about your birth control product. Contact Teva Canada Ltd. by calling toll-free at 1-800-268-4127, Option 3, or by email at druginfo@ if you have questions about this recall. Report any health product-related adverse reactions or complaints to Health Canada Également disponible en français SOURCE Health Canada (HC) View original content to download multimedia: Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

Long-lasting HIV prevention shot heads toward approval
Long-lasting HIV prevention shot heads toward approval

Yahoo

time6 hours ago

  • Yahoo

Long-lasting HIV prevention shot heads toward approval

June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store